Focada exclusivamente no desenvolvimento, 
                                        produção e promoção de produtos farmacêuticos especializados

Material Fact – Sale of Control – Closing



BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, in addition to the Material Facts of October 21st and 28th, 2019, hereby informs that it was notified by Knight Therapeutics Inc. (“Knight”), through its wholly owned subsidiary 11718991 Canada Inc. (“Buyer”), that the closing of the sale of 51,21%[1] of the shares issued by GBT (“Sale of Control”) has occurred on this date.

As previously announced, the Buyer confirmed it will conduct the mandatory tender offer for the acquisition of the remaining shares and BDRs of GBT, as set forth in Article 12 of the Bylaws of GBT, in similar terms of the Sale of Control (“MTO”).

Finally, the new composition and election of the members of the Company’s Board of Directors, approved by the shareholders’ meeting of November 25th, 2019 are in full force and effect as of this date.

The Company will keep its shareholders and the market in general informed on the developments of the events mentioned in this material fact, in compliance with applicable legislation, including all details related to the MTO.

[1] Excluding shares/BDRs held in treasury.

Montevideo, November 29, 2019

Claudio Coracini
Legal Representative in Brasil

Updated on 11/29/2019 at 10:45 pm